This suggests that targeting the vulnerability of this kind of AML cells, such as CEBPAbi whose C/EBPα-p42 is ineffective and C/EBPα-p30 is elevated, in the face of ER stress inducers can be a potential therapeutic strategy. The gene discussed is CEBPA; the disease is acute myeloid leukemia.